Vitamin K prophylaxis for preterm infants

Paul Clarke1

  • 1Neonatal Intensive Care Unit, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom. paul.clarke@nnuh.nhs.uk

Early Human Development
|January 29, 2010
PubMed

Insights

Vitamin K prophylaxis is standard for preterm infants, but optimal dosage and status assessment need more research. Current practices vary widely, highlighting a need for standardized, evidence-based guidelines.

Area of Science:

  • Neonatal medicine
  • Pediatric pharmacology
  • Biochemistry

Background:

  • Vitamin K prophylaxis is a routine treatment for preterm infants worldwide.
  • Despite widespread use, optimal dosage and administration methods remain unclear.
  • Limited research exists on vitamin K status post-prophylaxis in this vulnerable population.

Purpose of the Study:

  • To review current vitamin K prophylaxis practices in preterm infants.
  • To identify gaps in knowledge regarding optimal dosing and status assessment.
  • To highlight the need for evidence-based guidelines for vitamin K administration.

Main Methods:

  • Literature review of existing studies on vitamin K prophylaxis in preterm neonates.
  • Analysis of current clinical practices and guidelines.
  • Identification of research gaps and areas for future investigation.

Main Results:

  • Significant variability exists in current vitamin K prophylaxis regimens (dose, route, formulation).
  • There is a lack of data on the long-term vitamin K status of preterm infants post-prophylaxis.
  • Current practices are not consistently based on refined, population-specific evidence.

Conclusions:

  • Standardization of vitamin K prophylaxis for preterm infants is warranted.
  • Further research is crucial to determine optimal dosing and assess vitamin K status.
  • Evidence-based guidelines are needed to ensure safe and effective vitamin K administration.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Determination of Michaelis Constant and Maximum Elimination Rate01:20

Determination of Michaelis Constant and Maximum Elimination Rate

The Michaelis constant (KM) and the theoretical maximum process rate (Vmax) are vital parameters in the Michaelis-Menten equation, central to many biochemical reactions. They provide essential insights into enzyme kinetics and drug metabolism.
These parameters can be estimated by analyzing plasma concentration data post-drug administration. A notable example of this application is phenytoin, a drug with capacity-limited kinetics. It's recommended that phenytoin should be administered at two...